168 related articles for article (PubMed ID: 37357936)
21. The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.
Chen YQ; Gao LL; Kong LC; Guan XH; Yang H; Li YF; Lv ZY; Zhang XC; Liang HY; Chen HJ; Wu YL; Huang J; Yang JJ
Cancer Treat Res Commun; 2023; 35():100684. PubMed ID: 36716535
[TBL] [Abstract][Full Text] [Related]
22. Utility of secretagogin as a marker for the diagnosis of lung neuroendocrine carcinoma.
Baykara Y; Xiao Y; Yang D; Yakirevich E; Maleki S; Garcia-Moliner M; Wang LJ; Huang CK; Lu S
Virchows Arch; 2022 Jul; 481(1):31-39. PubMed ID: 35357570
[TBL] [Abstract][Full Text] [Related]
23. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
[TBL] [Abstract][Full Text] [Related]
24. Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56.
Sakakibara R; Kobayashi M; Takahashi N; Inamura K; Ninomiya H; Wakejima R; Kitazono S; Yanagitani N; Horiike A; Ichinose J; Matsuura Y; Nakao M; Mun M; Nishio M; Okumura S; Motoi N; Ito T; Miyazaki Y; Inase N; Ishikawa Y
Am J Surg Pathol; 2020 Jun; 44(6):757-764. PubMed ID: 32118626
[TBL] [Abstract][Full Text] [Related]
25. Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma.
Matsumura Y; Umemura S; Ishii G; Tsuta K; Matsumoto S; Aokage K; Hishida T; Yoshida J; Ohe Y; Suzuki H; Ochiai A; Goto K; Nagai K; Tsuchihara K
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2159-70. PubMed ID: 25989941
[TBL] [Abstract][Full Text] [Related]
26. Lung neuroendocrine neoplasms: recent progress and persistent challenges.
Rekhtman N
Mod Pathol; 2022 Jan; 35(Suppl 1):36-50. PubMed ID: 34663914
[TBL] [Abstract][Full Text] [Related]
27. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
28. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
30. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of immunohistochemical subtyping in patients with small cell lung cancer.
Chiang CL; Huang HC; Luo YH; Shen CI; Chao HS; Tseng YH; Chou TY; Schrump DS; Yeh YC; Chen YM
Lung Cancer; 2024 Feb; 188():107473. PubMed ID: 38232600
[TBL] [Abstract][Full Text] [Related]
32. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
33. Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.
Westerman BA; Neijenhuis S; Poutsma A; Steenbergen RD; Breuer RH; Egging M; van Wijk IJ; Oudejans CB
Clin Cancer Res; 2002 Apr; 8(4):1082-6. PubMed ID: 11948117
[TBL] [Abstract][Full Text] [Related]
34. SOX11 is a sensitive and specific marker for pulmonary high-grade neuroendocrine tumors.
Yu L; Dong Y; Xue J; Xu S; Wang G; Kuang D; Duan Y
Diagn Pathol; 2022 Jan; 17(1):2. PubMed ID: 34996493
[TBL] [Abstract][Full Text] [Related]
35. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.
Jiang SX; Kameya T; Shinada J; Yoshimura H
Mod Pathol; 1999 Apr; 12(4):362-9. PubMed ID: 10229500
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma.
Papaxoinis G; Bille A; McLean E; Nonaka D
Histopathology; 2022 Aug; 81(2):205-214. PubMed ID: 35544410
[TBL] [Abstract][Full Text] [Related]
37. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
[TBL] [Abstract][Full Text] [Related]
38. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y
Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities.
Yamada Y; Belharazem-Vitacolonnna D; Bohnenberger H; Weiß C; Matsui N; Kriegsmann M; Kriegsmann K; Sinn P; Simon-Keller K; Hamilton G; Graeter T; Preissler G; Ott G; Schölch S; Nakajima N; Yoshizawa A; Haga H; Date H; Thomas RK; Petrini I; Giaccone G; Ströbel P; Marx A
Cell Death Dis; 2022 Nov; 13(11):979. PubMed ID: 36402755
[TBL] [Abstract][Full Text] [Related]
40. NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms.
Lee JH; Shin DH; Lee SY; Park JY; Kim SY; Hwang CS; Lee HJ; Na JY; Kim JY
Histol Histopathol; 2022 Nov; 37(11):1091-1098. PubMed ID: 36282054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
